Published in
BioMed Central, Respiratory Research, 1(17), 2016
DOI: 10.1186/s12931-016-0363-2
Links
- ORCID
- ORCID
- ORCID
- BioMed Central
- [respiratory-research.com] | PDF
- [dx.doi.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [dspace.library.uu.nl] | PDF
- [pure.rug.nl] | PDF
- [www.rug.nl] | PDF
Tools
Advanced glycation endproducts and their receptor in different body compartments in COPD
,
Alen Faiz,
Eef D. Telenga,
Maarten van den Berge ,
Leo Koenderman,
Jan-Willem J. Lammers,
H. Marike Boezen,
Antoon J. M. van Oosterhout,
Monique E. Lodewijk,
Wim Timens ,
Dirkje S. Postma,
Nick ten Hacken
and other authors.
Full text: Download
Abstract
Abstract Background Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by chronic airway inflammation and emphysema, and is caused by exposure to noxious particles or gases, e.g. cigarette smoke. Smoking and oxidative stress lead to accelerated formation and accumulation of advanced glycation end products (AGEs), causing local tissue damage either directly or by binding the receptor for AGEs (RAGE). This study assessed the association of AGEs or RAGE in plasma, sputum, bronchial biopsies and skin with COPD and lung function, and their variance between these body compartments. Methods Healthy smoking and never-smoking controls ( n = 191) and COPD patients ( n = 97, GOLD stage I-IV) were included. Autofluorescence (SAF) was measured in the skin, AGEs (pentosidine, CML and CEL) and sRAGE in blood and sputum by ELISA, and in bronchial biopsies by immunohistochemistry. eQTL analysis was performed in bronchial biopsies. Results COPD patients showed higher SAF values and lower plasma sRAGE levels compared to controls and these values associated with decreased lung function ( p